The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron Deficiency
The Effects of Iron Treatment on Malaria, Typhoid and Measles Vaccine Response in Kenyan Infants With Iron Deficiency: A Randomized Controlled Trial
Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination.
In this double-blind randomized controlled trial, we aim to assess: (1) whether ID impairs R21/Matrix-M, Typhim VI and measles (MR) vaccine response, (2) whether iron treatment at time of vaccination improves vaccine response.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Nicole Stoffel, PhD
- 電話番号:+41 044 632 83 93
- メール:nicole.stoffel@hest.ethz.ch
研究連絡先のバックアップ
- 名前:Lara Del Curto, MSc
- 電話番号:+41 0774212070
- メール:lara.delcurto@pharma.ethz.ch
研究場所
-
-
Kwale County
-
Msambweni、Kwale County、ケニア、80404
- 募集
- Msambweni District Hospital
-
コンタクト:
- Edith Mwasi, MD
- メール:edithmwasi@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Subject's caregiver is willing and able to give informed consent
- Male or Female, 6 months (+/- 2 weeks) of age
- Mother ≥15 years of age
- Iron deficient (erythrocyte zinc protoporphyrin (ZnPP) >61 μmol/mol heme) or anemic (hemoglobin (Hb) <105 g/L)
Exclusion Criteria:
- Severely anemic (Hb <70 g/L)
- Hemoglobinopathies HbCC, HbSC, or HbSS
- Malaria, Measles or Typhoid vaccination prior to enrollment
- Medical condition that precludes study involvement
- Iron supplementation 2 weeks before enrollment
- Acute or chronic infection (e.g. HIV)
- Wasted (length for height z score of ≥-2) or underweight (weight for age z score ≥-2).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Iron treatment group
daily multivitamin + daily iron syrup from age 6 to 10 months |
Iron syrup administered daily from 6 to 10 months of age. Multivitamin syrup administered daily from 6 to 10 months of age. R21-Matrix/M vaccine administered in 3 doses at 7, 8 and 9 months of age. Measles-Rubella vaccine administered at 9 months of age. |
|
他の:Control group
daily multivitamin syrup from age 6 to 10 months |
Multivitamin syrup administered daily from 6 to 10 months of age. R21-Matrix/M vaccine administered in 3 doses at 7, 8 and 9 months of age. Measles-Rubella vaccine administered at 9 months of age. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
NANP-specific IgG
時間枠:At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG antibodies targeting the NANP repeat region of the circumsporozoite protein (CSP) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Anti-measles IgG
時間枠:At 10 months of age (1 month after MR vaccine administration)
|
IgG antibodies targeting measles antigen |
At 10 months of age (1 month after MR vaccine administration)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Anti-typhoid IgG
時間枠:At 10 months of age (1 month after Typhim VI administration)
|
IgG antibodies targeting typhoid antigen |
At 10 months of age (1 month after Typhim VI administration)
|
|
C-terminal-specific IgG
時間枠:At 10 months of age (1 month after 3rd R21/Matrix-M dose)
|
IgG antibodies targeting the C-terminal region of CSP |
At 10 months of age (1 month after 3rd R21/Matrix-M dose)
|
|
C-terminal-specific IgG
時間枠:At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
IgG antibodies targeting the C-terminal region of CSP |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
C-terminal-specific IgG
時間枠:At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
IgG antibodies targeting the C-terminal region of CSP |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
|
NANP-specific IgG
時間枠:At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
IgG antibodies targeting the NANP repeat region of CSP |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
NANP-specific IgG
時間枠:At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
IgG antibodies targeting the NANP repeat region of CSP |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
|
Full-length CSP-specific IgG
時間枠:At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG antibodies targeting the full-length CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgM
時間枠:At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgM antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgA
時間枠:At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgA antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG4
時間枠:At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG4 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG3
時間枠:At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG3 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG2
時間枠:At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG2 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG1
時間枠:At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG1 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
IgG avidity to measles antigen
時間枠:At 10 months of age (1 month after MR vaccine administration)
|
Avidity index for IgG binding to measles antigen |
At 10 months of age (1 month after MR vaccine administration)
|
|
IgG avidity to typhoid antigen
時間枠:At 10 months of age (1 month after Typhim VI administration)
|
Avidity index for IgG binding to typhoid antigen |
At 10 months of age (1 month after Typhim VI administration)
|
|
IgG avidity to NANP-specific CSP
時間枠:At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Avidity index for IgG binding to NANP CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
IgG avidity to C-terminal CSP
時間枠:At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Avidity index for IgG binding to C-terminal CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Full-length CSP-specific IgG seropositivity
時間枠:At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
C-terminal-specific IgG seropositivity
時間枠:At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
C-terminal-specific IgG seropositivity
時間枠:At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
C-terminal-specific IgG seropositivity
時間枠:At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
|
NANP-specific IgG seropositivity
時間枠:At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG seropositivity
時間枠:At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
NANP-specific IgG seropositivity
時間枠:At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Inhibition of Plasmodium falciparum sporozoite-invasion of HC-04 hepatic cells
時間枠:At 10 months of age (1 months after the 3rd R21/Matrix-M dose)
|
Exploratory in vitro assay on IgG functionality in lowest and highest responders |
At 10 months of age (1 months after the 3rd R21/Matrix-M dose)
|
|
Opsonic phagocytosis of CSP-coated beads by THP-1 cells
時間枠:At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Exploratory in vitro assay of IgG opsonization functionality in lowest and highest responders |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells
時間枠:At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Exploratory in vitro assay performed in lowest and highest responders |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Antibody levels against a panel of antigens associated with malaria exposure in the previous year
時間枠:At 7 months of age (baseline)
|
Exploratory in all participants |
At 7 months of age (baseline)
|
協力者と研究者
スポンサー
協力者
捜査官
- 主任研究者:Nicole Stoffel, PhD、ETH Zurich
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- MEMA
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。